Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety reported to be useful for the treatment of cancer.

St. Jude Children’s Research Hospital has divulged molecular glue degraders comprising cereblon (CRBN) binding agents covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and/or DNA-binding protein ikaros (IKZF1) targeting moiety acting as GSPT1 and/or IKZF1 degradation and GSPT1 and/or IKZF1/CRBN interaction inducers reported to be useful for the treatment of cancer.

GSK plc has identified pyrazine compounds reported to be useful for the treatment of malaria infection by Plasmodium falciparum.

Novartis AG has synthesized naphthyridinone derivatives acting as K(ir) 3.1/3.4 (GIRK1/4; KCNJ3/5) IKACh channel blockers reported to be useful for the treatment of bradyrhythmic arrhythmia, bradycardia, atrial fibrillation, heart block, hypotension, primary aldosteronism, sick sinus syndrome and vasovagal syncope, among others.

Remix Therapeutics has disclosed compounds acting as RNA splicing modulators reported to be useful for the treatment of cancer and Huntington’s disease.

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors have been reported by Shanghai Jemincare Pharmaceuticals Co. Ltd. to be potentially useful for the treatment of cancer, fibrosis, inflammation, pain, neurodegeneration, autoimmune, metabolic and cardiovascular disorders, among others.

Several Lario Therapeutics Ltd. patents describe new voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) antagonists reported to be useful for the treatment of neurodegeneration, epilepsy, Parkinson’s disease, cerebral vasospasm, pain, CDKL5 deficiency, endocrine and neurodevelopmental disorders, among others.

Kallyope Inc. patent details new AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of type 2 diabetes, allergy, cancer, depression, nutrition disorders, obesity, psoriasis and ulcerative colitis, among others.

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via linker.

Ocean University of China has identified imidazothiazole derivatives acting as MAPK-interacting kinase 1 (MNK1) and MNK2 inhibitors.